Mr. Stern has over 20 years of biopharmaceutical experience and has launched numerous brands into the US and Global Women’s Health, HIV, and Metabolic markets. Prior to joining Symbiomix, he served as the Chief Commercial Officer at Celmatix, responsible for launching the company’s first product, Polaris™ into the US Fertility market and establishing several research collaborations. Mr. Stern was also the Executive Vice President of Global Commercial Operations for OvaScience, leading the global launch of Augment®. Before that, he served as Senior Vice President and Head of the Global Business Franchise for Fertility at Merck Serono, responsible for the company’s market leading Fertility portfolio world-wide. Mr. Stern also worked at EMD Serono as Executive Vice President of Endocrinology, managing commercial operations in the Fertility, HIV and Growth Hormone markets. He began his career at Organon Pharmaceutical in Woman’s Health. Mr. Stern earned his bachelor’s degree in biology at Brandeis University and holds an MBA from the F.W. Olin School of Business at Babson College. He is a member of the European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine, and serves as an independent board member of California Cryobank.

 Endocrinology